Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-12-01
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm
Participants take Asiaticoside tablets 60mg tid for 12 weeks
Asiaticoside tablets
Asiaticoside tablets 60mg tid for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Asiaticoside tablets
Asiaticoside tablets 60mg tid for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
* Able and willing to provide written informed consent.
Exclusion Criteria
* Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²).
* Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
* Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year.
* Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids).
* Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months.
* Current smoker or habitual smoker within the past 3 months.
* type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications.
* Pregnancy or planning pregnancy, or breastfeeding.
* Unable to complete a 3-month follow-up due to health conditions or relocation.
* Participation in any clinical study within the past 4 weeks.
* Other conditions considered by investigators as unsuitable for participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
JINGJING JIANG, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2025-710
Identifier Type: -
Identifier Source: org_study_id